Talphera (NASDAQ:TLPH) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Talphera (NASDAQ:TLPH) posted its quarterly earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, Zacks reports.

Talphera Price Performance

TLPH remained flat at $1.29 during trading hours on Wednesday. The company had a trading volume of 399,191 shares, compared to its average volume of 863,856. The company’s 50-day moving average price is $1.06 and its 200-day moving average price is $0.68. Talphera has a one year low of $0.38 and a one year high of $1.45. The firm has a market capitalization of $60.13 million, a price-to-earnings ratio of -3.22 and a beta of 0.15.

Institutional Trading of Talphera

An institutional investor recently raised its position in Talphera stock. Group One Trading LLC lifted its stake in Talphera, Inc. (NASDAQ:TLPH) by 3,224.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,415 shares of the company’s stock after purchasing an additional 29,500 shares during the period. Group One Trading LLC owned about 0.07% of Talphera worth $27,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on TLPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Wednesday, October 8th. Wall Street Zen raised Talphera to a “hold” rating in a research report on Saturday, November 1st. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.